Nock, S. (2021) The dual kinase and scaffold function of Btk downstream of GPVI and CLEC-2 in platelets. PhD thesis, University of Reading. doi: 10.48683/1926.00101688

Holbrook, L.-M., Keeton, S. J., Sasikumar, P., Nock, S., Gelzinis, J., Brunt, E., Ryan, S., Pantos, M. M., Verbetsky, C. A., Gibbins, J. M. ORCID: https://orcid.org/0000-0002-0372-5352 and Kennedy, D. R. (2021) Zafirlukast is a broad-spectrum thiol isomerase inhibitor that inhibits thrombosis without altering bleeding times. British Journal of Pharmacology, 178 (3). pp. 550-563. ISSN 1476-5381 doi: 10.1111/bph.15291

Nicolson, P. L., Nock, S. H., Hinds, J., Garcia-Quintanilla, L., Smith, C. W., Campos, J., Brill, A., Pike, J. A., Khan, A. O., Poulter, N. S., Kavanagh, D. M., Watson, S., Watson, C. N., Clifford, H., Huissoon, A. P., Pollitt, A. Y. ORCID: https://orcid.org/0000-0001-8706-5154, Eble, J. A., Pratt, G., Watson, S. P. and Hughes, C. E. ORCID: https://orcid.org/0000-0002-9790-5820 (2020) Low dose Btk inhibitors selectively block platelet activation by CLEC-2. Haematologica, 105 (1). ISSN 1592-8721 doi: 10.3324/haematol.2019.218545

Nicolson, P. L. R., Hughes, C. E. ORCID: https://orcid.org/0000-0002-9790-5820, Watson, S., Nock, S. H., Hardy, A. T., Watson, C. N., Montague, S. J., Clifford, H., Huissoon, A. P., Malcor, J.-D., Thomas, M. R., Pollitt, A. Y. ORCID: https://orcid.org/0000-0001-8706-5154, Tomlinson, M. G., Pratt, G. and Watson, S. P. (2018) Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation to GPVI. Haematologica, 103 (12). pp. 2097-2108. ISSN 1592-8721 doi: 10.3324/haematol.2018.193391

Bye, A. P. ORCID: https://orcid.org/0000-0002-2061-2253, Unsworth, A. J., Desborough, M. J., Hildyard, C. A. T., Appleby, N., Bruce, D., Kriek, N., Nock, S. H., Sage, T., Hughes, C. E. ORCID: https://orcid.org/0000-0002-9790-5820 and Gibbins, J. M. ORCID: https://orcid.org/0000-0002-0372-5352 (2017) Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Advances, 1 (26). pp. 2610-2623. ISSN 2473-9529 doi: 10.1182/bloodadvances.2017011999